Development and validation of an ELISA to study panitumumab pharmacokinetics

0 avis

Development and validation of an ELISA to study panitumumab pharmacokinetics

Archive ouverte

Edité par CCSD ; Future Science -

International audience. Panitumumab is a monoclonal antibody directed against EGFR that is approved for the treatment of metastatic colorectal cancer. To investigate its pharmacokinetics and concentration-response relationship, a validated assay is required.

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

Archive ouverte | Ternant, David | CCSD

International audience

Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients

Archive ouverte | Lobet, Sarah | CCSD

International audience. Background and ObjectiveCetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal immunoglobulin (Ig)G1 antibody, has been approved for the treatment of metastatic colorectal canc...

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Archive ouverte | Lioger, Bertrand | CCSD

International audience. Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen am...

Chargement des enrichissements...